Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

Crizotinib is an oral kinase inhibitor approved for the treatment of ALK-rearranged non-small-cell lung cancer (NSCLC). The clinical benefits of crizotinib in patients with brain metastases have not been previously studied. Patients with advanced ALK-rearranged NSCLC enrolled onto clinical trial PRO...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2015-06, Vol.33 (17), p.1881-1888
Hauptverfasser:	Costa, Daniel B, Shaw, Alice T, Ou, Sai-Hong I, Solomon, Benjamin J, Riely, Gregory J, Ahn, Myung-Ju, Zhou, Caicun, Shreeve, S Martin, Selaru, Paulina, Polli, Anna, Schnell, Patrick, Wilner, Keith D, Wiltshire, Robin, Camidge, D Ross, Crinò, Lucio
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - therapeutic use Brain Neoplasms - diagnosis Brain Neoplasms - drug therapy Brain Neoplasms - genetics Brain Neoplasms - secondary Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - secondary Cranial Irradiation Disease-Free Survival Female Gene Rearrangement Humans Kaplan-Meier Estimate Lung Neoplasms - pathology Magnetic Resonance Imaging Male Middle Aged ORIGINAL REPORTS Protein Kinase Inhibitors - therapeutic use Pyrazoles - therapeutic use Pyridines - therapeutic use Radiosurgery Randomized Controlled Trials as Topic Receptor Protein-Tyrosine Kinases - genetics Retrospective Studies Tomography, X-Ray Computed Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!